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Background We aimed to assess the point prevalence of microalbuminuria (MAU) in a sample of 
unselected consecutive primary-care attendees, with particular focus on patients with diabetes mellitus 
(with and without additional concomitant diseases) and those with hypertension.   
Design Cross-sectional observational study in a nationwide representative sample of 1912 primary-
care practices and a patient population consisting of 39 125 primary-care attendees. Diagnoses for 
diabetes, hypertension and co-morbidities were provided by the treating physician and complemented 
by blood pressure (BP) measurements and selected lab tests. Screening for microalbuminuria (> 20 
and < 200 lg/ml) was done with a spot urine dipstick test.   
Results The clinical diagnosis of nephropathy was assigned to 7.6% of patients. The point prevalence 
of MAU was 19.0% in the total sample; the proportion was 33.6% in diabetics whereas the diagnosis 
was assigned to only 7.1% in the total sample. Amongst diabetic patients with MAU, 92.6% had BP 
above the target value of < 130/80 mmHg. Frequency rates rose with increasing BP (e.g. 20.6% in 
diabetic patients with BP< 120/70mmHg, and 36.3% in diabetic patients with BP> 140/90 mmHg). Of 
note, patients with MAU had a higher burden of co-morbidity compared to those without MAU.   
Conclusions We found a high prevalence of MAU in primary care, particularly in diabetic patients. 
The frequency of MAU was closely related to the BP level and the degree of co-morbidity. The 
present study underlines the magnitude of the problem of MAU in primary care, and should serve as a 
starting point to initiate measures to address this important public health issue.     
 
Keywords: nephropathy, microalbuminuria, prevalence, primary care, risk factors, screening  
 
Sponsorship: This study was supported by an unrestricted educational grant by Sanofi-Aventis 
Deutschland GmbH, Berlin, Germany.   
 
 
Introduction   
 
It is widely acknowledged that in patients with either type 1 or type 2 diabetes, 
microalbuminuria is a powerful predictor of cardiovascular events and overt diabetic 
nephropathy [1,2]. It is also a predictor of cardiovascular risk in non-diabetic individuals [3].   
 
As reflected in the recent recommendations of the American Diabetes Association, there is 
broad consensus that testing for microalbuminuria is an integral part of the management of 
diabetic patients [4]. The rationale for this recommendation is based on the fact that, first, 
efficient drug intervention strategies targeted at the renin–aldosterone–angiotensin system 
(RAAS) are available, namely angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs). Second, early treatment provides a window of 
opportunity as reflected by the much stronger risk reduction in early as compared to late 
stages of diabetic nephropathy [5,6].   
 
Recent evidence suggests marked deficiencies in the management of diabetic patients by 
general practitioners in several countries, suggesting that there might be a lack of awareness 
for the importance of this issue, and consequently a high proportion of diabetic patients 
remain underdiagnosed and undertreated [6,7]. Several studies in the general population have 
pointed out that microalbuminuria is a frequent finding, with estimates ranging between 12 
and 32% [8–10]. Unfortunately there is a lack of recent data, describing the prevalence of 
recognized and unrecognized microalbuminuria among primary-care patients, notably among 
diabetic patients, who represent a patient group at a particularly high risk.   
 
Therefore we set up a large nationwide primary-care study, named the Hypertension and 
Diabetes Risk Screening and Awareness Study (HYDRA), screening over 40 000 unselected 
primary-care attendees, to fill this knowledge gap [11]. The aims of the present analysis were: 
to evaluate the frequency of albuminuria in all primary-care patients and, in particular, in a 
subset of patients with diabetes mellitus; to examine the frequency of microalbuminuria in the 
presence of hypertension and/or diabetes; and to assess the association between 
microalbuminuria and cardiovascular co-morbidities, focusing on micro- and macrovascular 
complications.   
 
 
Material and methods   
 
Study design   
 
HYDRA is a cross-sectional point prevalence study, based on a two-step observational 
epidemiological design (for details see http://www.hydra-studie.de) [11]. In step one, a 
nationwide representative sample of doctors (medical practitioners, generalists, general 
internists) was recruited on the basis of 1060 regional segments (according to the criteria of 
the Institute for Medical Statistics (IMS), Frankfurt am Main, Germany), clustered into 
geographical areas for which primary-care doctor addresses were available. Participating 
doctors completed a pre-study questionnaire regarding personal and structural characteristics 
of each practice and to assess self-perceived qualifications and attitudes related to recognition, 
diagnosis, and care of patients with hypertension, diabetes and other conditions. A total of 
1912 primary-care doctors were included (response rate of 79.1%).   
 
The second step consisted of a target day assessment (two half days) of all consecutive 
patients attending the doctor’s office, irrespective of the reason for contact (target day 
response rate: 74.2%). All attending patients filled out a self-report patient questionnaire 
(attitudes and health behaviours, awareness of diagnostic status, self-reported treatment, 
compliance and problems with current medication), followed by a structured doctor’s clinical 
appraisal, including documentation of lab test findings from the charts, blood pressure (BP) 
measurements, and assessment of microalbuminuria and blood glucose in urine spot samples. 
The full dataset comprised 45 125 patients. Valid information on microalbuminuria, diabetes 
mellitus and arterial hypertension was available from 39 025 patients, which provide the 
dataset for the present analysis. Analyses checking for representativeness were able to show 
that this sample was grossly comparable to the full dataset; with patients being slightly 
younger and having slightly lower rates of concomitant illnesses (data not shown).   
 
Diagnostic conventions   
 
Diagnostic findings on arterial hypertension, diabetes mellitus and other diseases in this report 
are based exclusively on the doctor’s clinical appraisal. This included rating of the current 
presence of hypertension and diabetes using: not present, borderline, mild/ moderate, 
severe/extreme, and indicating the presence or absence of 22 predefined somatic and mental 
disorders. Additionally, for all primary target diagnoses of the study (hypertension, diabetes) a 
wide range of clinical (drug and non-drug treatment, medication, comorbidity, compliance) 
and course information (age at first diagnosis, treatment, etc.) were assessed, including 
patient-specific evaluation of the degree to which the doctor believed that diabetes and/or 
hypertension was controlled. The assessment of patients’ actual BP reported in this paper was 
based on a single measurement of systolic and diastolic BP. It was measured by indirect cuff 
sphygmomanometry after several minutes of rest in the sitting position, as recommended [12].   
 
The diagnosis of nephropathy was assigned if the doctor indicated that he knew that the 
patient had diabetic nephropathy (including borderline cases) before enrolling the patient into 
the study. For the detection of albuminuria in a spot urine sample, the semi-quantitative 
dipstick Micral-Test II (Boehringer Mannheim, Germany), was used [13], as it has proved 
useful for screening purposes in a primary-care setting [14]. A positive test result was 
assigned when the test indicated 20, 50 or 100 mg/ml albuminuria. Thus, the term albuminuria 
in the present study stands for a positive one-time positive dipstick test.   
 
Body weight and height information were taken from the patients’ questionnaire. Body mass 
index (kg/m2) was calculated from these self-reported data and classified according to 
international conventions [15].   
 
Statistical analyses   
 
Differences in microalbuminuria rates were quantified with odds ratios (ORs) from logistic 
regressions [16] while adjusted for age group, sex and gender x age group and calculating 
robust confidence intervals for observations clustered within primary-care settings [17]. All 
analyses were conducted using the Stata 8 software package (StataCorp LP, College Station, 
Texas, USA).   
 
 
Results   
 
Sample characteristics   
 
Table 1 displays key demographic and clinical characteristics of the patients. Typical for a 
primary-care sample, there was a considerable proportion of elderly patients (aged 65 years 
and above), a high proportion of overweight and obese patients, and a considerable proportion 
of patients with diabetes, hypertension or both, respectively (men>women). A total of 7.3% of 
patients had nephropathy as diagnosed by the physician, and 15.9% had diabetes.   
 
Frequency of microalbuminuria   
 
Table 2 shows that a substantial proportion of all primarycare attendees (total sample: 19.0%) 
had microalbuminuria. Rates were almost three times as high as the rates of patients 
diagnosed as having nephropathy (including borderline) by the physician. Positive findings 
were age-related and a moderate gender difference was found (men>women beyond age 40). 
Rates of microalbuminuria were particularly high among diabetic patients, especially when 
these patients had hypertension (overall 35.6%). High microalbuminuria rates were also found 
in the presence of microvascular complications (retinopathy, nephropathy, neuropathy, sexual 
dysfunction and diabetic feet) and macrovascular complications (coronary artery disease, 
stroke, peripheral arterial disease, etc.). Microalbuminuria was associated not only with a 
higher number of cardiovascular complications but also with an absolute increase in co-
morbidity (number of diagnoses, data not shown).   
 
Microalbuminuria in patients with hypertension   
 
Table 3 displays the prevalence rates of microalbuminuria according to BP categories in the 
total sample, as well as in patients without diabetes versus with diabetes. In nondiabetic 
patients with a BP below 140/90mmHg the prevalence rates were comparable (15.6, 13.3 and 
14.1% respectively) and increased beyond 140/90mmHg to 19.8%. In contrast to this, an 
increase in BP was closely related to an increase in microalbuminuria in diabetic patients over 
the whole range of BP categories, to a high of 36.3% in patients with BP>140/90 mmHg. In 
the presence of macrovascular complications (coronary artery disease, stroke, peripheral 
arterial disease, etc.), microalbuminuria rates in diabetics were further increased throughout 
all BP categories (maximum: 41.3%).   
 
Microalbuminuria in patients with co-morbidities   
 
Table 4 shows the association of microalbuminuria with 15 frequent diseases, in the total 
sample as well as divided into patients with and without diabetes. In almost all conditions, the 
rates of microalbuminuria were increased compared to those patients without the respective 
disease. The diseases associated with the highest increase in risk for microalbuminuria (as 
indicated by high ORs) in the total sample, but also in diabetic patients, were (in declining 
order) diabetic feet, retinopathy, neuropathy, peripheral arterial disease, left ventricular 
hypertrophy and sexual dysfunction.   
 
Patients with microalbuminuria had a higher co-morbidity burden, expressed as categories of 
the number of diseases, and there was a monotonic relationship between the degree of co-
morbidity and the prevalence of microalbuminuria. The respective risk was substantially 
increased compared to patients without microalbuminuria, as indicated by the ORs; for 
example, the odds of having two to three additional diseases was increased in the former 
group (no additional diseases) by about 60% (OR 1.6), and of having four to five additional 
diseases by about 120% (OR 2.2). Similar risk increases were seen in both diabetic and non-
diabetic patients with microalbuminuria (detailed data not shown).   
 
 
Discussion   
 
There are three key findings in our study. First, the frequency of albuminuria in primary care 
is high: every fifth patient in our study had a positive spot test finding. Secondly, in both 
diabetic and hypertensive patients prevalence rates were higher than in non-diabetic, 
normotensive patients. The presence of high BP levels (<140/90mmHg) in the total cohort, 
particularly in diabetic patients, as well as the presence of microvascular or macrovascular 
complications, was associated with high rates of microalbuminuria. Thirdly, patients with 
microalbuminuria had a substantially higher burden of co-morbidity compared to those 
without microalbuminuria.   
 
Strengths and limitations   
 
Before discussing these key findings, the strength and limitations of this paper should be 
considered. The strengths of the study are: that it concerns a large nationwide, representative 
sample of family doctors’ offices and of patients; and that the study design allowed us to 
obtain information on diagnostic interventions, cardiovascular disease management and co-
morbidity, not only from the physician, but also from the patient. This allowed the assessment 
of information deficits both on the patients’ and physicians’ side. According to Lum [18] the 
dipstick test as used in this study ‘is inexpensive, easy and rapid to perform’ and effective at 
all prevalence rates. Sensitivity values of the Micral II test compared with 24-h nephelometry 
were 93% and specificity 94%, in a random sample of primary-care attendees [13]. Using the 
albumin/creatinine ratio would have provided increased sensitivity, but this measurement was 
impractical for logistic reasons. Yet, random urine specimens are more variable than 24-h or 
morning urine samples, presumably reflecting diurnal variation of BP and glomerular 
filtration rate (GFR), but receiver-operating characteristics indicate acceptable specificity and 
sensitivity [19]. An important limitation is that, for logistic reasons, the number of items 
assessed had to be limited; unfortunately data on smoking status could not be obtained. 
Likewise, albuminuria could only be assessed on a single occasion. This does not allow 
estimation of how many patients would be positive or negative on a second testing. Derived 
from data obtained by the Third National Health and Nutrition Examination Survey 
(NHANES III) [20], one could estimate that at least 65% of the negatively tested patients will 
test positive on a subsequent occasion.   
 
Point prevalence of a positive dipstick test   
 
It is noteworthy that our estimated prevalence of 19% is generally in good accordance with 
findings previously reported in various other epidemiological studies, none of which, 
however, was performed in primary care, which is a high-risk population compared with the 
community. The prevalence of microalbuminuria was reported to be 23% in France [21]. In 
Canada, the prevalence was 32% in diabetic and 15% in non-diabetic individuals [22]. In a 
recent Australian study [23], overt proteinuria was found in 0.8% of a random general 
population sample under 44 years and 7% over 65 years. It was increased by a factor of four 
in diabetic individuals. In NHANES III the prevalence of microalbuminuria in diabetics was 
29% (about 8% in non-diabetics). On the other hand, a previous German study in general 
practitioner offices [24] found microalbuminuria in 4% of normotensive, 10% of hypertensive 
and 17% of diabetic individuals, respectively. Overt proteinuria was present in 8% of 
diabetics under 60 years of age and in 13% of diabetics aged over 60 years. In 85 421 adult 
inhabitants of Groningen, microalbuminuria was reported in 16% of diabetic patients [25].   
 
It is of note that the usual cut-off for microalbuminuria, which was also applied in our study, 
is to be considered arbitrary in the light of current research. Diabetic patients with baseline 
albumin excretion rate values of 20–30 mg/24 h had an accelerated decline in GFR, and an 
elevated risk for cardiovascular events [26]. According to current data from the community-
based Framingham cohort with middle-aged, non-hypertensive, non-diabetic individuals, low 
levels of urinary albumin excretion well below the current microalbuminuria threshold 
predicted the development of cardiovascular disease [27]. The data have been confirmed by a 
study of Romundstad et al. [28], which found a similar relationship between 
microalbuminuria and cardiovascular risk.   
 
The major determinant of microalbuminuria in diabetic [29,30] as well as in non-diabetic 
individuals is hypertension [24,25]. There is also sound evidence that microalbuminuria is 
related to sub-diabetic glycaemia [31] as well as to inflammatory markers and endothelial 
dysfunction [32] as a potential reflection of atherosclerosis [33]. Overall, increasing levels of 
albuminuria are an independent indicator of cardiovascular risk factors and cardiovascular 
morbidity [25,34], more so in men than in women [35].   
 
Co-morbidities   
 
Earlier cross-sectional studies suggest that microalbuminuria, a marker of glomerular 
hyperfiltration and endothelial dysfunction, may be a feature of hypertension and a marker of 
target-organ damage [24]. Urinary albumin excretion predicts BP progression in nondiabetic, 
non-hypertensive individuals incrementally better than established risk factors, and at levels 
well below the conventional threshold for microalbuminuria [36]. Our study highlights the 
size of the problem in primary care: the albuminuria prevalence in the total sample, even in 
patients below the hypertension thresholds (tight control <120/70mmHg, conventional r140/ 
90 mmHg), was in the order of 15% (in diabetics 21– 29%), which shows the proportion of 
patients at increased risk for hypertension, organ damage and cardiovascular events. Our 
analysis of patients with various concomitant diseases sheds light on the fact that a series of 
other conditions is associated with a high prevalence of microalbuminuria, and thus with the 
risks described above. In this context, it was disappointing that achieved BP values (the most 
important modifiable risk factor) were far off the recommended targets for high-risk 
populations [4]. This observation is in line with previous observations of non-compliance with 
best-practice guidelines in type 2 diabetics, even by self-selected physicians [37].   
 
Perspective: treatment options   
 
The single microalbuminuria measurements in our study would have to be confirmed by 
another test finding (rule: two out of three must be positive) according to American Diabetes 
Association (ADA) recommendations, before treatment is initiated [4]. But if the diagnosis of 
microalbuminuria is established, aggressive lowering of elevated BP will be mandatory in 
diabetics, along with general measures (protein restriction, glycaemic control) [4]. 
Antihypertensive drugs with proven renoprotective efficacy are the first choice. The 
Irbesartan Microalbuminuria in Type-2-Diabetes Trial (IRMA-2) with irbesartan [5] has 
shown that the progression of nephropathy can be slowed under ARB therapy. Even in 
patients with manifest nephropathy, this effect translates into decreased disease progression 
[6].   
 
In conclusion, our analysis shows the magnitude of the problem in primary care: a large 
proportion of patients has microalbuminuria and therefore is at increased risk. From a public 
health standpoint, microalbuminuria screening in type 2 diabetics is cost effective [38] and 
standard management programmes in screened patients have been shown to cause major cost 
saving [39]. Consequently, we recommend standard screening of primary-care patients to 
offer patients at risk the option of early modification of risk factors. For patients with 
microalbuminuria or overt renal dysfunction, an aggressive RAAS-based approach to 
hypertension management, combining potent BP control with proven renoprotection, holds 
the key for therapy targeted towards long-term cardiovascular protection. This study should 
serve as the basis to address the highly prevalent problem of microalbuminuria in primary 
care.     
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